In the case of circular hair loss (alopecia areata), the affected hair loses – it can range from individual lysines to the loss of the entire head. The suffering is great, but there is now hope in the form of tablets that have now been approved by the US authorities.
The slap of Hollywood star Will Smith at the Oscars drew attention to the hair loss of his wife, Jada Pinkett Smith. Sharon Battiste, a new “bachelor” in the country, recently revealed that she suffers from alopecia areata. But there is hope. In the US, it has now been officially green for an anti-circular hair loss drug that people with disabilities can take orally. In the studies, patients returned 80 percent of their hair coverage.
Remedy for circular hair loss
This condition, which often manifests itself as irregular baldness, affects more than 300,000 people in the United States each year.1 According to Alopecia Areata Deutschland eV, there are 1.5 million people in Germany with various forms of inflammatory hair loss.2
Now there is good news for them. The US Food and Drug Administration (FDA) has now approved Eli Lilly’s Olumiant as a drug to treat alopecia areata. These are tablets that are already available on the US market – formerly for the treatment of rheumatoid arthritis and other autoimmune diseases.
Also interesting: Lupus erythematosus – causes, symptoms, treatment
Tablets tested in two studies
The currently approved tablets have been tested in two studies involving patients who had lost at least 50 percent of their hair for more than six months. The measure of effectiveness was the number of patients who returned at least 80 percent of their hair coverage by week 36.
In both clinical trials, the researchers randomly assigned 1,200 subjects to a study and control group. The first group received an anti-circular hair loss drug, while the second group received a placebo.3
Also interesting: The study identifies the most effective remedy for hair loss in men
The participants’ hair grew again
In Study AA-1, 22 percent of 184 patients who received 2 milligrams of Olumiant and 35 percent of 281 patients who received 4 milligrams of Olumiant achieved adequate scalp coverage, compared with 5 percent of 189 patients who received placebo. .
In Study AA-2, 17 percent of the 156 patients who received 2 milligrams of Olumiant and 32 percent of the 234 patients who received 4 milligrams of Olumiant achieved adequate scalp hair coverage, compared with 3 percent of the 156 patients who received placebo. .
In short, in both clinical trials, a third of the participants enjoyed new hair growth.
The drug can alleviate suffering
“Alopecia areata is a crazy journey full of chaos, confusion and deep sadness for many patients,” explains study leader Dr. Brett King, professor of Yale Medical School at University Declaration4. “It’s amazing to have a drug that can help people get through it and get back to normal, to be able to get to know themselves and show up to others.”